{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T13:27:09Z","timestamp":1770298029249,"version":"3.49.0"},"publisher-location":"New York, NY","reference-count":22,"publisher":"Springer US","isbn-type":[{"value":"9781071637739","type":"print"},{"value":"9781071637746","type":"electronic"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1007\/978-1-0716-3774-6_5","type":"book-chapter","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T10:02:25Z","timestamp":1709287345000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimized Pre-analytical Handling Protocol for Blood-Based Biomarkers of Alzheimer\u2019s Disease"],"prefix":"10.1007","author":[{"given":"Alexander","family":"Jethwa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"St\u00f6ckl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,2]]},"reference":[{"key":"5_CR1","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"key":"5_CR2","doi-asserted-by":"publisher","first-page":"e17591","DOI":"10.7759\/cureus.17591","volume":"13","author":"M Esang","year":"2021","unstructured":"Esang M, Gupta M (2021) Aducanumab as a novel treatment for Alzheimer\u2019s disease: a decade of hope, controversies, and the future. Cureus 13:e17591. https:\/\/doi.org\/10.7759\/cureus.17591","journal-title":"Cureus"},{"key":"5_CR3","unstructured":"FDA (2023) FDA grants accelerated approval for Alzheimer\u2019s disease treatment. January 06, 2023. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-disease-treatment. Accessed 15 Feb 2023"},{"key":"5_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.dadm.2019.02.002","volume":"11","author":"M R\u00f3zga","year":"2019","unstructured":"R\u00f3zga M, Bittner T, Batrla R, Karl J (2019) Preanalytical sample handling recommendations for Alzheimer\u2019s disease plasma biomarkers. Alzheimers Dement (Amst) 11:291\u2013300. https:\/\/doi.org\/10.1016\/j.dadm.2019.02.002","journal-title":"Alzheimers Dement (Amst)"},{"key":"5_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2147\/DNND.S228939","volume":"9","author":"J Rasmussen","year":"2019","unstructured":"Rasmussen J, Langerman H (2019) Alzheimer\u2019s disease \u2013 why we need early diagnosis. Degener Neurol Neuromuscul Dis 9:123\u2013130. https:\/\/doi.org\/10.2147\/DNND.S228939","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"5_CR6","doi-asserted-by":"publisher","unstructured":"Kurz C, St\u00f6ckl L, Schrurs I, Suridjan I, G\u00fcrsel SU, Bittner T, Jethwa A, Perneczky R (2023) Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer\u2019s disease. J Neurochem 165(1):95\u2013105. https:\/\/doi.org\/10.1111\/jnc.15757","DOI":"10.1111\/jnc.15757"},{"key":"5_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L, Lantero-Rodriguez J, Pascoal TA, Su\u00e1rez-Calvet M, Rosa-Neto P et al (2022) Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol 18:400\u2013418. https:\/\/doi.org\/10.1038\/s41582-022-00665-2","journal-title":"Nat Rev Neurol"},{"key":"5_CR8","doi-asserted-by":"publisher","first-page":"e20200861","DOI":"10.1084\/jem.20200861","volume":"217","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med 217:e20200861. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"key":"5_CR9","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jalz.2014.02.004","volume":"11","author":"K Blennow","year":"2015","unstructured":"Blennow K, Dubois B, Fagan AM, Lewczuk P, de Leon MJ, Hampel H (2015) Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer\u2019s disease. Alzheimers Dement 11:58\u201369. https:\/\/doi.org\/10.1016\/j.jalz.2014.02.004","journal-title":"Alzheimers Dement"},{"key":"5_CR10","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, Janelidze S, Benedet AL, Rodriguez JL, Chamoun M, Savard M, Kang MS, Therriault J et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19:422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"key":"5_CR11","doi-asserted-by":"publisher","first-page":"100005","DOI":"10.1016\/j.bionps.2019.100005","volume":"1","author":"R Khoury","year":"2019","unstructured":"Khoury R, Ghossoub E (2019) Diagnostic biomarkers of Alzheimer\u2019s disease: a state-of-the-art review. Biomark Neuropsychiatry 1:100005. https:\/\/doi.org\/10.1016\/j.bionps.2019.100005","journal-title":"Biomark Neuropsychiatry"},{"key":"5_CR12","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC et al (2017) Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement 13:841\u2013849. https:\/\/doi.org\/10.1016\/j.jalz.2017.06.2266","journal-title":"Alzheimers Dement"},{"key":"5_CR13","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T, Kishi Y, Kakeya T, Waragai M, Kondo M, Allsop D, Tokuda T (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegener 12:63. https:\/\/doi.org\/10.1186\/s13024-017-0206-8","journal-title":"Mol Neurodegener"},{"key":"5_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jneumeth.2018.10.025","volume":"319","author":"H Zetterberg","year":"2019","unstructured":"Zetterberg H (2019) Blood-based biomarkers for Alzheimer\u2019s disease \u2013 an update. J Neurosci Methods 319:2\u20136. https:\/\/doi.org\/10.1016\/j.jneumeth.2018.10.025","journal-title":"J Neurosci Methods"},{"key":"5_CR15","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-020-00595-5","volume":"12","author":"JD Doecke","year":"2020","unstructured":"Doecke JD, Ward L, Burnham SC, Villemagne VL, Li Q-X, Collins S, Fowler CJ, Manuilova E, Widmann M, Rainey-Smith SR et al (2020) Elecsys CSF biomarker immunoassays demonstrate concordance with amyloid-PET imaging. Alzheimers Res Ther 12:36. https:\/\/doi.org\/10.1186\/s13195-020-00595-5","journal-title":"Alzheimers Res Ther"},{"key":"5_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, Fowler C, Li Q-X, Martins R, Rowe C et al (2018) High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554:249\u2013254. https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"key":"5_CR17","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1016\/j.jalz.2018.01.010","volume":"14","author":"O Hansson","year":"2018","unstructured":"Hansson O, Seibyl J, Stomrud E, Zetterberg H, Trojanowski JQ, Bittner T, Lifke V, Corradini V, Eichenlaub U, Batrla R et al (2018) CSF biomarkers of Alzheimer\u2019s disease concord with amyloid-\u03b2 PET and predict clinical progression: a study of fully automated immunoassays in BioFINDER and ADNI cohorts. Alzheimers Dement 14:1470\u20131481. https:\/\/doi.org\/10.1016\/j.jalz.2018.01.010","journal-title":"Alzheimers Dement"},{"key":"5_CR18","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.1002\/alz.12756","volume":"18","author":"O Hansson","year":"2022","unstructured":"Hansson O, Edelmayer RM, Boxer AL, Carrillo MC, Mielke MM, Rabinovici GD, Salloway S, Sperling R, Zetterberg H, Teunissen CE (2022) The Alzheimer\u2019s association appropriate use recommendations for blood biomarkers in Alzheimer\u2019s disease. Alzheimers Dement 18:2669\u20132686. https:\/\/doi.org\/10.1002\/alz.12756","journal-title":"Alzheimers Dement"},{"key":"5_CR19","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/alz.12316","volume":"17","author":"O Hansson","year":"2021","unstructured":"Hansson O, Batrla R, Brix B, Carrillo MC, Corradini V, Edelmayer RM, Esquivel RN, Hall C, Lawson J, Le Bastard N et al (2021) The Alzheimer\u2019s association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid \u03b2 and tau. Alzheimers Dement 17:1575\u20131582. https:\/\/doi.org\/10.1002\/alz.12316","journal-title":"Alzheimers Dement"},{"key":"5_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3233\/JAD-2012-120058","volume":"30","author":"AD Watt","year":"2012","unstructured":"Watt AD, Perez KA, Rembach AR, Masters CL, Villemagne VL, Barnham KJ (2012) Variability in blood-based amyloid-beta assays: the need for consensus on pre-analytical processing. J Alzheimers Dis 30:323\u2013336. https:\/\/doi.org\/10.3233\/JAD-2012-120058","journal-title":"J Alzheimers Dis"},{"key":"5_CR21","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jalz.2013.10.007","volume":"10","author":"HM Snyder","year":"2014","unstructured":"Snyder HM, Carrillo MC, Grodstein F, Henriksen K, Jeromin A, Lovestone S, Mielke MM, O\u2019Bryant S, Sarasa M, Sj\u00f8gren M et al (2014) Developing novel blood-based biomarkers for Alzheimer\u2019s disease. Alzheimers Dement 10:109\u2013114. https:\/\/doi.org\/10.1016\/j.jalz.2013.10.007","journal-title":"Alzheimers Dement"},{"key":"5_CR22","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/alz.12510","volume":"18","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J, Ball AJ, Blennow K, Dage JL, Fandos N, Hansson O, Hirtz C, Janelidze S et al (2021) Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the standardization of Alzheimer\u2019s blood biomarkers (SABB) working group. Alzheimers Dement 18:1484\u20131497. https:\/\/doi.org\/10.1002\/alz.12510","journal-title":"Alzheimers Dement"}],"container-title":["Methods in Molecular Biology","Biomarkers for Alzheimer\u2019s Disease Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-3774-6_5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T18:13:12Z","timestamp":1715019192000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-3774-6_5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9781071637739","9781071637746"],"references-count":22,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-3774-6_5","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"assertion":[{"value":"2 March 2024","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}